TL;DR: TB-500 is a synthetic peptide commercially marketed as a fragment of Thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein with documented roles in G-actin sequestration, cell migration, angiogenesis, and tissue repair. The published research base is predominantly preclinical, rodent and in vitro models, centered on the parent Tβ4 protein rather than the specific TB-500 fragment itself. No large human RCTs for any tissue-repair indication have been published as of 2026. TB-500 is not FDA approved and is explicitly prohibited by WADA under Section S2.
Research-Use Disclaimer: This article is for educational and research reference purposes only. TB-500 is a research peptide, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research on Thymosin beta-4 and related peptides. For adults 21+ with a research interest only.
What Is TB-500? Definition, Origins, and the Tβ4 Relationship
TB-500 is the commercial name for a synthetic peptide fragment that corresponds to amino acids 17–23 of Thymosin beta-4 (Tβ4), a ubiquitous, naturally occurring 43-amino-acid protein found in virtually all mammalian nucleated cells. The sequence most commonly associated with the TB-500 commercial product is Ac-LKKTETQ (or variants thereof), selected on the basis that this region of the Tβ4 molecule is associated with actin-binding activity and cell migration in published research.
The scientific literature on this area is built almost entirely around full-length Thymosin beta-4, not the TB-500 fragment specifically. Researchers evaluating claims associated with TB-500 should be aware of this distinction: the mechanistic studies cited in this article document Tβ4 biology, and extrapolation to the truncated commercial fragment, while a reasonable scientific hypothesis, has not been independently validated with the same depth of evidence.
What Is the Core Mechanism? How Thymosin Beta-4 Interacts with Actin
The foundational mechanism of Thymosin beta-4, and the basis for all downstream tissue-repair hypotheses, is its role as a G-actin sequestering protein. Understanding this mechanism is essential context for interpreting the broader research literature.
What Does “G-Actin Sequestration” Mean in Research?
Actin exists in two forms in cells: G-actin (globular, monomeric, unpolymerized) and F-actin (filamentous, polymerized). Rapid transitions between these forms drive cell movement, migration, and shape changes. Thymosin beta-4 binds G-actin with micromolar affinity, holding actin monomers in a readily available but unpolymerized pool. When cells receive signals to migrate, during wound healing, immune activation, or angiogenesis, this sequestered pool releases and polymerizes rapidly, enabling fast cytoskeletal reorganization.
According to PubMed, a landmark 1992 study by Cassimeris et al. published in The Journal of Cell Biology demonstrated that Thymosin beta-4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes, and that chemoattractant stimulation reduces the G-actin/Tβ4 complex as polymerization proceeds, consistent with a dynamic regulatory role in cell motility (PMID: 1447300).
A 2007 review by Hannappel published in Annals of the New York Academy of Sciences traces the history of this discovery, noting that in 1990 Safer and colleagues first recognized that thymosin beta-4 sequesters G-actin with a dissociation constant in the micromolar range that allows fast binding and release, establishing beta-thymosins as the main intracellular G-actin-sequestering peptides in most vertebrate cells (PMID: 17468232).
What Research Contexts Has Thymosin Beta-4 Been Studied In?
Based on articles retrieved from PubMed, the Thymosin beta-4 literature spans several distinct preclinical research contexts. The following summarizes each major area with primary source citations.
1. Wound Healing and Skin Repair Models
A 2012 review by Goldstein, Hannappel, Sosne, and Kleinman published in Expert Opinion on Biological Therapy, among the most comprehensive summaries of Tβ4 biology, documents that after injury, Tβ4 is released by platelets, macrophages, and other cell types to protect cells and tissues from further damage, reduce apoptosis and inflammation, bind to actin, and promote cell migration including the mobilization, migration, and differentiation of stem/progenitor cells which form new blood vessels and regenerate tissue. The review also notes Tβ4 decreases myofibroblast numbers in wounds, resulting in reduced scar formation (PMID: 22074294).
A 2010 review by Philp and Kleinman (NIH/NIDCR) published in Annals of the New York Academy of Sciences specifically reviewed animal model evidence across dermal, corneal, and cardiac wound repair, concluding that Tβ4 studies in various animal models of disease and repair have provided the scientific foundation for ongoing clinical trials in dermal, corneal, and cardiac wound repair, indicating that the preclinical evidence was considered sufficient to advance to human trials in those specific contexts (PMID: 20536453).
2. Corneal and Ocular Repair Models
Corneal wound healing is one of the most extensively studied Tβ4 research contexts and the furthest advanced toward clinical translation. A 2002 study by Sosne, Szliter, Kleinman, and colleagues published in Experimental Eye Research demonstrated that topical Tβ4 treatment in a mouse alkali corneal injury model produced accelerated re-epithelialization at all time points and decreased PMN infiltration at 7 days post-injury compared to controls, with decreased mRNA levels for pro-inflammatory cytokines including IL-1β, MIP-1α, and MCP-1 (PMID: 11950239).
A 2018 review by Sosne published in Expert Opinion on Biological Therapy narrates the translational arc from bench to bedside, noting that Tβ4 has entered Phase 3 human clinical trials for dry eye disease and neurotrophic keratopathy, representing the most advanced clinical development of any Tβ4-related compound and one of the few contexts where human trial data exists (PMID: 30063853).
A 2023 review by Sosne and Berger published in International Immunopharmacology further describes Tβ4 as currently in Phase 3 human clinical trials for dry eye disease, with prior work demonstrating that topical Tβ4 as an adjunct reduces inflammatory mediators and PMN infiltrates while enhancing bacterial killing and wound healing pathway activation in P. aeruginosa keratitis models (PMID: 37018981).
3. Cardiac Research Models
A 2018 review by Hinkel, Klett, Bähr, and Kupatt published in Expert Opinion on Biological Therapy characterizes Tβ4’s documented role in cardiac preclinical research, noting that during cardiac development Tβ4 appears essential for vascularization of the myocardium, and in adult organisms Tβ4 has anti-inflammatory properties, increases myocyte and endothelial cell survival accompanied by differentiation of epicardial progenitor cells, with overexpression enhancing micro- and macrovasculature in ischemic myocardium and improving cardiac function in diabetic and dyslipidemic pig ischemic heart models (PMID: 30063857).
A 2015 review by Goldstein and Kleinman published in Expert Opinion on Biological Therapy synthesizes the broader preclinical-to-clinical translation picture, summarizing that Tβ4 has been used successfully in several clinical trials involving tissue repair and regeneration, with significant advances in understanding its direction of stem cell maturation and regeneration following injury, providing the scientific foundation for ongoing and projected trials in eye injuries, dermal wounds, cardiac repair following myocardial infarction, and brain healing following stroke (PMID: 26096726).
4. Neurological and Cell Migration Models
A 1993 study by Border and colleagues published in Journal of Neurochemistry investigated beta-thymosin expression in developing rat cerebellum, finding that Tβ4 expression in premigratory granule cells and in growing neuronal processes is consistent with the possibility that beta-thymosins are involved in the dynamics of actin polymerization during migration and process extension of neurons, establishing early evidence for Tβ4’s role in cell migration contexts beyond peripheral tissue (PMID: 8245965).
5. Actin-Sequestration, Nitric Oxide, and HIF-1α
A 2014 study by Ryu, Kang, and Moon published in PLoS ONE investigated interactions between Tβ4, nitric oxide, and hypoxia-inducible signaling in cell culture models, finding that the actin-sequestering protein Tβ4 is a novel target of hypoxia-inducible nitric oxide and HIF-1α regulation, with NO production and Tβ4 expression both increased under hypoxic conditions, and SNAP-1-induced cell migration decreased when Tβ4 was inhibited via siRNA, suggesting a mechanistic link between hypoxic signaling pathways and Tβ4-mediated cell motility (PMID: 25271630).
What Is the Honest Evidence Tier for TB-500?
Representing the evidence tier accurately requires distinguishing between two distinct bodies of work: the extensive preclinical literature on full-length Thymosin beta-4, and the very limited research on the specific TB-500 commercial fragment. The following table summarizes the landscape as documented in published literature:
| Evidence Level | Status for TB-500 / Thymosin beta-4 (as of 2026) |
|---|---|
| Human randomized controlled trials | Not available for tissue repair; Tβ4 has entered Phase 3 trials for dry eye / corneal indications only; no human RCT data for the TB-500 fragment specifically |
| Peer-reviewed animal model studies (Tβ4 parent protein) | Substantial, rodent models across wound, cardiac, corneal, musculoskeletal, and neurological contexts |
| In vitro / cell culture evidence (Tβ4 parent protein) | Present and consistent, cell migration, actin dynamics, angiogenesis pathway activation |
| Independent research on TB-500 fragment specifically | Very limited; most commercially referenced studies are on full-length Tβ4 and are extrapolated to the fragment |
| FDA approval status | Not approved for any human use |
| WADA status | Prohibited, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) |
The critical limitation to state plainly: The scientific rationale for TB-500 rests on extrapolating from Tβ4 biology to a truncated fragment. This is a coherent mechanistic hypothesis, the actin-binding region of Tβ4 does correspond to the fragment used, but it is not the same as having independent, peer-reviewed evidence for the specific commercial peptide. The absence of human RCTs for any tissue-repair indication, and the absence of independent peer review for the TB-500 fragment itself, places this compound firmly in the preclinical-only evidence tier.
What Is TB-500’s Regulatory and Anti-Doping Status?
FDA Status (United States)
TB-500, as a synthetic research peptide, is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. The FDA has not authorized any therapeutic indication for TB-500 or for Thymosin beta-4 outside of the specific clinical trial contexts in which Tβ4 is currently being studied (corneal indications). Researchers should consult current FDA guidance directly for the most up-to-date classification status.
WADA Status (World Anti-Doping Agency)
TB-500 and Thymosin beta-4 are explicitly prohibited by the World Anti-Doping Agency under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics of the WADA Prohibited List. This is distinct from the S0 classification applied to some other research compounds; S2 specifically targets peptide growth factors and related substances due to their potential for performance-enhancing effects. The S2 prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules, and encompasses both the full-length Tβ4 protein and synthetic fragments or mimetics associated with it. Athletes in sanctioned sports should be aware that TB-500 is a prohibited substance under anti-doping regulations.
Frequently Asked Questions About TB-500
Is TB-500 FDA approved?
No. TB-500 is not approved by the FDA for any therapeutic use in humans. It is classified as a research peptide with no approved indication, no authorized human dosing protocol, and no legal status as a drug or dietary supplement in the United States. The related full-length protein Thymosin beta-4 has entered Phase 3 clinical trials for specific corneal indications, but this does not confer any approval to the TB-500 commercial fragment.
What does the TB-500 and Thymosin beta-4 research actually show?
Based on articles retrieved from PubMed, the peer-reviewed literature on Thymosin beta-4 documents consistent preclinical findings across G-actin sequestration, cell migration promotion, angiogenesis in injury contexts, anti-inflammatory activity, and tissue-repair effects in rodent models spanning wound healing, corneal injury, cardiac ischemia, and musculoskeletal contexts. The specific TB-500 commercial fragment has minimal independent published research. Human clinical data for tissue repair is absent; the most advanced human clinical work on Tβ4 relates to dry eye disease and corneal wound repair.
What is TB-500’s evidence tier?
TB-500 is a Tier 2 compound in the Legendary Labz framework, the parent protein Thymosin beta-4 has multiple peer-reviewed animal model studies with consistent mechanistic findings, but lacks the human RCT evidence required for Tier 1 classification, and the specific fragment has even less independent research than the full protein. Full evidence-tier methodology is documented in the guide.
Is TB-500 prohibited by WADA?
Yes. Thymosin beta-4 and related peptide fragments including TB-500 are prohibited by the World Anti-Doping Agency under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This prohibition applies in-competition and out-of-competition and covers all athletes subject to WADA-compliant anti-doping programs. Note that TB-500 falls under S2 (not S0), reflecting its classification as a peptide growth factor-related substance rather than simply a non-approved substance.
Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. TB-500 / Thymosin beta-4 is prohibited by WADA under Section S2. Must be 21+.